Lupin has received USFDA approval for Clomipramine Hydrochloride capsules and Potassium Chloride for oral solution. The drug will be made available in the strengths of 25 mg, 50 mg, and 75 mg and it is a generic version of SpecGx LLC’s Anafranil capsules in the same strengths. The capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). According to market estimates, Anafranil capsules in the same strengths had annual sales of around $109.6 million in the US.
It may be noted that, the company has also received USFDA approval to market its Potassium Chloride for oral solution USP, 20 mEq. It is the generic version of Pharma Research Software Solution LLC’s Potassium Chloride for oral solution, 20 mEq. According to market estimates, the product had annual sales of around $105 million in the US.
Company Profile : Lupin Ltd
Leave a Reply